News

Your contact person

Manager PR & Communications Jan Phillip Denkers

Evotec is excited to provide a new compound that has the potential to improve the lives of many women

Evotec receives US$ 18 m grant for women's health

Evotec SE announced that the Company has received a US$ 18 m grant from the Bill & ...

Read more …
(Picture: ©denisismagilov - adobe.stock.com)

Quantum Physics in Proteins

A new analytical technique is able to provide hitherto unattainable insights into the extremely rapid dynamics of biomolecules. The team of developers, led by Abbas ...

Read more …

Evotec Initiates US IPO

Evotec expects to grant the underwriters a 30-day option to purchase up to an additional 3,300,000 ADSs. The sale of the ADSs and the issuance ...

Read more …
The company will operate as Eppendorf SE with immediate effect. Picture: © Eppendorf SE

Eppendorf SE: conversion to European public limited company

"We are convinced that we have taken the right step at the right time with this modern legal form, which is very common in ...

Read more …

Evotec: Collaboration with Bristol Myers Squibb

Evotec SE announced that its collaboration with Bristol Myers Squibb has been expanded to include a new cell type, triggering a payment of $ 9.0 ...

Read more …
Image: ©Eppendorf AG

Eppendorf Award 2022: Call for Entries

The Eppendorf Award for Young European Investigators, endowed with 20,000 EUR, is granted annually to an early career scientist in Europe for outstanding contributions to ...

Read more …
The facility employs J.POD® technology that uses autonomous clean rooms to run small, highly intensified production processes, thereby reducing the cost of biologics manufacturing. (Picture: ©Benjamin Benschneider)

Just - Evotec Biologics opens J.POD® 1 US

Evotec SE announced the opening of the company’s late-stage clinical and commercial biologics cGMP manufacturing facility (J.POD® 1 US) in Redmond, Washington. ...

Read more …
Funds to be used to obtain clinical proof of concept in two programs and to accelerate innovative pipeline focused on restoring immune tolerance to treat and potentially cure autoimmune diseases (Picture: ©Topas Therapeutics)

Topas Therapeutics Extends Series B

Topas Therapeutics GmbH (Topas), a private biotechnology company developing immune tolerance-inducing drugs to treat and potentially cure a variety of autoimmune diseases, today ...

Read more …
Evotec creates further opportunities for long-term growth with "Campus Levi-Montalcini" in Verona. (Picture: ©Z S / Unsplash)

Evotec creates long-term growth opportunities

Evotec SE announced that Evotec has added significant opportunities for further, long-term growth by acquiring the Verona site from GlaxoSmithKline SpA (“GSK”). ...

Read more …
Fraunhofer ITMP uses high-tech methods for cell-based drug screening. (Picture: ©Fraunhofer ITMP)

Stem Cell-Based Translation

The North as a hub for global stem cell research: The 2021 Annual Meeting of the International Society for Stem Cell Research (ISSCR) was scheduled ...

Read more …
Dr. Tanmay Bharat, Sir William Dunn School of Pathology, University of Oxford (Picture: ©Eppendorf AG)

Eppendorf Award for Young European Investigators 2021

In 2021, Eppendorf AG, the Hamburg life sciences company, is presenting its highly prestigious research prize for the 26th time. The independent ...

Read more …
Indivumed is using nRavel™ for target discovery and drug development programs. (Picture: ©Jackie Niam/stock.adobe.com)

Indivumed Launches the nRavel AI Platform

Indivumed GmbH (“Indivumed”) today announced the launch of nRavel™, a unique AI discovery platform for oncology and precision medicine. The platform combines ...

Read more …